This chapter explores the complexities of FDA approval for MDMA therapy, particularly related to addiction treatment, and the ongoing dialogue needed to clarify trial designs. It highlights serious concerns about mental health issues reported during trials, the transparency of clinical processes, and the societal implications of medicalizing psychedelics. The discussion includes critiques of existing PTSD treatments and assesses the financial and ethical dimensions of emerging psychedelic therapies.